Inhibition of Plasmodium falciparum proliferation in vitro by ribozymes

• Published in: The Journal of biological chemistry 1997-07, Vol.272 (27), p.16940-16945
• Main Authors: Flores, M V, Atkins, D, Wade, D, O'Sullivan, W J, Stewart, T S
• Format: Article
• Language: English
• Subjects: Animals; Antimalarials - chemical synthesis; Antimalarials - therapeutic use; Base Sequence; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing) - genetics; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing) - metabolism; Cell Division; Cells, Cultured; DNA Transposable Elements; Humans; Molecular Sequence Data; Oligonucleotides - metabolism; Plasmodium falciparum; Plasmodium falciparum - cytology; Plasmodium falciparum - genetics; RNA, Catalytic - metabolism; RNA, Catalytic - therapeutic use; RNA, Messenger - metabolism; Tetrahydrofolate Dehydrogenase - genetics; Tetrahydrofolate Dehydrogenase - metabolism
• ISSN: 0021-9258
• DOI: 10.1074/jbc.272.27.16940

Catalytic RNA (ribozymes) suppressed the growth of the human malarial parasite Plasmodium falciparum in vitro. The phosphorothioated hammerhead ribozymes targeted unique regions of the P. falciparum carbamoyl-phosphate synthetase II gene. The P. falciparum carbamoyl-phosphate synthetase II gene encodes the first and limiting enzyme in the pathway, and its mRNA transcript contains two large insert regions absent in other carbamoyl-phosphate synthetases, including that from humans. These inserts are ideal targets for nucleic acid therapy. Exogenous delivery of ribozymes to cultures reduced malarial viability up to 55% at 0.5 microM ribozyme concentrations, which is significantly greater than control levels (5-15% reduction), suggesting a sequence-specific inhibition. This inhibition was shown to be stage-specific, with optimal inhibitions being detected after 24 h, coincident with maximal production of the carbamoyl-phosphate synthetase enzyme in the course of the life cycle of the parasite. A decrease in total carbamoyl-phosphate synthetase activity was observed only in cultures treated with the ribozymes. The task of developing alternative therapeutic agents against malaria is urgent due to the evolution of drug-resistant strains of P. falciparum, the most virulent of all human malarial parasites. Another critical issue to be addressed is the possibility of eliminating or reducing any systemic toxicity to the host, which can potentially be provided by nucleic acid therapy. This work is the first reported assessment of the ability of ribozymes as antimalarials. Ribozyme inhibition assays can also aid in identifying important antimalarial loci for chemotherapy. The malarial parasite can, in turn, be a useful in vivo host to study the catalysis and function of new ribozyme designs.